Xspray Pharma Ab Publ

Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients’ quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product dasatinib is pending FDA approval and has received orphan drug status in the US. Xspray Pharma’s management team has extensive experience from the pharmaceutical industry. The company is based in Stockholm and shares are traded on Nasdaq Stockholm.